首页   >  

所有产品分类

所有产品

信号通路

研究领域

天然产物

抗体

多肽

催化剂

杂质对照品

医药中间体

基础原料

Epigenetics

结构式 货号 产品名称 CAS号
Bomedemstat ditosylate 结构式
BCP44102 Bomedemstat ditosylate 1990504-72-7
Bomedemstat is a lysine-specific histone demethylase 1 (LSD1) inhibitor with antineoplastic activity.
Pulrodemstat 结构式
BCP44101 Pulrodemstat 1821307-10-1
Pulrodemstat is a potent and orally active LSD1 inhibitor. CC-90011 binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4, respectively. CC-90011 exhibits potent on-target induction of cellular differentiation in acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cell lines, and antitumor efficacy in patient-derived xenograft (PDX) SCLC models.
Ilginatinib 结构式
BCP44119 Ilginatinib 1239358-86-1
Ilginatinib is an orally bioavailable, small molecule inhibitor of Janus-associated kinase 2 (JAK2) and Src-family kinases, with potential antineoplastic activity. JAK2/Src inhibitor NS-018 competes with ATP for binding to JAK2 as well as the mutated form JAK2V617F, thereby inhibiting the activation of JAK2 and downstream molecules in the JAK2/STAT3 (signal transducer and activator of transcription 3) signaling pathway that plays an important role in normal development, particularly hematopoiesis. In addition, NS-018 inhibits the Src family tyrosine kinases. This eventually leads to the induction of tumor cell apoptosis.
Senaparib 结构式
BCP44003 Senaparib 1401682-78-7
Senaparib is an orally bioavailable inhibitor of the nuclear enzymes poly (ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity.
RVX297 结构式
BCP43937 RVX297 1044871-04-6
RVX297 is a BD2 selective inhibitor of BET bromodomains. It is structurally related to the clinical compound RVX-208. It has significant implications on differential gene expression, which possibly can be further linked to the specific disease indication. It is currently undergoing phase III clinical trials for the treatment of cardiovascular diseases.
NVP-TNKS656 结构式
BCP28685 NVP-TNKS656 1419949-20-4
NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor with IC50 of 6 nM, and is > 300 fold selectivity against PARP1 and PARP2.
NI-42 结构式
BCP43848 NI-42 1884640-99-6
NI 42 is a high affinity BRPF inhibitor (Kd values are 40, 210 and 943 nM for BRPF1B, 2 and 3, respectively). Also exhibits modest activity at BRD9 (Kd = 1130 nM). Exhibits selectivity for BRPF over 44 other bromodomains. Orally bioavailable.
GSK3685032 结构式
BCP43733 GSK3685032 GSK3685032
GSK3685032, a potent first-in-class DNMT1-selective inhibitor that was shown via crystallographic studies to compete with the active-site loop of DNMT1 for penetration into hemi-methylated DNA between two CpG base pairs.
Bisindolylmaleimide VIII acetate 结构式
BCP43574 Bisindolylmaleimide VIII acetate 138516-31-1
Bisindolylmaleimide VIII acetate is a potent and selective protein kinase C (PKC) inhibitor with an IC50 of 158 nM for rat brain PKC.
GSK778 结构式
BCP43559 GSK778 2451862-42-1
GSK778, also known as iBET-BD1, is a potent and selective inhibitor of bromodomain (BRD) BD1, with IC50s of 75 nM (BRD2 BD1).
123下一页末页共 616 条记录 1 / 62 页 
2853530910